RUNX2 and leukemia: To stress the ability of RUNX2-CAR8 to clear WT leukemia, we used an ultra-low CAR+ dose (1e5), against which both CAR8ND and CAR8MD exhibit markers of exhaustion and fail to control leukemia (Figure S7A–C).